

Pegloticase (Krystexxa®)

Pegloticase is a recombinant, PEGylated uricase made from mammalian uricase via a genetically modified strain of *E. coli*. As an enzyme, it converts uric acid to allantoin, thus, reducing serum uric acid.

Resources from Manufacturer

[Patient Medication Guide](#)
[Full Prescribing Information](#)
[Patient Support Program](#)
[Financial Assistance](#)

FDA-Approved Indications and Dosing in Rheumatology

Pegloticase is indicated for the treatment of chronic gout in adult patients refractory to conventional therapy

Intravenous Dosing

- 8 mg IV every 2 weeks with or without methotrexate
 - May be given monotherapy if methotrexate is not clinically appropriate
 - If co-administered with weekly oral methotrexate and folic acid, start these agents at least 4 weeks prior to starting pegloticase infusions

Contraindications

- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- History of serious hypersensitivity to Pegloticase or any of its components

Warnings and Precautions

1. Anaphylaxis may occur with any infusion, pre-medicate and monitor patients
2. Infusion reactions may occur, pre-medicate and monitor patients
3. Avoid use in patients with G6PD deficiency
4. Congestive heart failure may occur, closely monitor following infusion
5. Gout flare prophylaxis is recommended for at least the first 6 months of therapy

continued

Adverse Reactions ($\geq 5\%$)

If co-administered with methotrexate:

- Gout flares
- Arthralgia
- COVID-19
- Nausea
- Fatigue

If pegloticase monotherapy:

- Gout flares
- Infusion reactions
- Nausea
- Contusion or ecchymosis
- Constipation
- Chest pain
- Anaphylaxis
- Vomiting

Medication Strength and Preparations

- For intravenous infusion: 8 mg/1 mL single-dose glass vials with latex-free, coated rubber stopper

Medication Administration and Storage

- Must be diluted before using. Do not administer as IV push or bolus.
- Pegloticase admixture should be only be given as IV infusion over no less than 120 minutes via gravity-feed, syringe-type pump or infusion pump
- Allow diluted solution of pegloticase to reach room temperature before administration. Never subject pegloticase vial or diluted pegloticase in infusions bags to artificial heating.
- Before preparation for use, store in carton to protect from light and refrigerate between 2°C to 8°C [36°F to 46°F]—do not freeze
- Diluted pegloticase in infusion bags is stable for 4 hours at 2°C to 8°C [36°F to 46°F] and at room temperature [20oC to 25oC, 68oF to 77oF].
- Do not shake

continued

Intravenous Administration Pre-infusion Checklist

■ Confirm the following:

- Negative for G6PD deficiency
- Serum uric acid levels are > 6 mg/dL, especially when 2 consecutive levels > 6 mg/dL noted
- Patient discontinued oral urate-lowering therapy before receiving pegloticase and it was not started while on pegloticase therapy
- Patient premedicated with antihistamines and corticosteroids to minimize risk of anaphylaxis and infusion reactions
- Patient on gout flare prophylaxis with either NSAIDs or colchicine beginning at least 1 week prior to initiation and continuing for at least 6 months from initiation unless medically contraindicated or not tolerated.

If unable to confirm above checklist items, notify the ordering provider before initiating the infusion therapy.

Intravenous Medication Preparation

1. Visually inspect vials for particulate matter and discoloration – do not use if either is present.
2. Use appropriate aseptic technique. Withdraw 1 mL from pegloticase vial into a sterile syringe. Inject into a single 250 mL bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP for IV infusion. Do not mix or dilute with other drugs.
3. Invert infusion bag containing dilute pegloticase solution a few times to ensure thorough mixing. Do not shake.
4. Use diluted pegloticase in infusion bags within 4 hours of dilution.

Managing Infusion Reactions

If an infusion reaction occurs during administration of pegloticase, the infusion may be slowed, or stopped and restarted at a slower rate at the discretion of the physician. Consider observing patients for 1-hour post-infusion since infusion reactions can occur after completion of infusion.

Updated June 2023–ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology (“ACR”) for informational purposes only, in furtherance of its educational mission. It is not a substitute for user’s independent medical discretion or decision making, nor a replacement for the manufacturer’s complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide (including without limitation, any adverse effects).